Cure My Disease

Don't miss your cure!

 Log in / Sign up

A mailed kit and a chat: a new push to screen more latina women for cervical cancer

NCT ID NCT06439706

Prevention Sponsor: Fox Chase Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

Researchers are testing whether a brief educational session helps Latina women who are overdue for cervical cancer screening use a mailed HPV self-sampling kit. Half of the participants receive the kit alone, and the other half also join a small-group session with a bilingual health educator. The study tracks how many women in each group return a self-collected sample for HPV testing, and whether the education makes self-sampling more acceptable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HPV self-sampling kit with or without small-group education led by a bilingual health educator
What this could lead to
If it works, this approach could make cervical cancer screening easier for Latina women who are overdue, potentially reducing cervical cancer rates in this group.
What could go wrong
This is a small feasibility study, so it may not show a clear benefit. Some women may still find self-sampling uncomfortable or difficult, and the results may not apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

108 people

The number who actually took part.

Started

Oct 2023

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 65 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Self-reported Hispanic/Latina ethnicity * Assigned female sex at birth * Age 30-65, consistent with guidelines for HPV DNA testing for cervical cancer screening * Speak and read English or Spanish * Computer or other device with internet connection * Overdue for cervical cancer screening (e.g., no cytology-based screening within the past 3 years; no hrHPV testing either alone or in combination with cytology in the past 5 years). Exclusion Criteria: * Prior diagnosis of cervical cancer or abnormality (e.g., dysplasia) * Had a hysterectomy/removal of the cervix * Compromised immune system (e.g., known HIV) * Women who self-report that they are pregnant or are within three months after a pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Uterine cervical neoplasm are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Uterine Cervical Neoplasms cervical cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Uterine cervical neoplasm

Contacts and locations

Locations

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.